MONTREAL, Oct. 6 /CNW/ -- Caprion Proteomics Inc. announced today that it
has been awarded a $12.9 million contract by the National Institute of Allergy
and Infectious Diseases (NIAID), a part of the US National Institutes of
Health, to carry out Biodefense research in the area of infectious disease
Under the contract to be performed over a five-year period, Caprion will
act as one of two NIAID Clinical Proteomics Centers for Infectious Disease &
Biodefense, and will employ its distinctive CellCarta(R) quantitative protein
profiling technologies to perform several large scale applied proteomics
projects using human clinical samples from patients with infectious diseases.
The projects will be aimed at the discovery, qualification, and verification
of candidate biomarkers with potential for clinical use to improve detection
and diagnosis and to monitor therapeutic and vaccine responses and
susceptibility to infection for diseases caused by various pathogens. This
second major Biodefense research contract awarded to Caprion by NIAID builds
on the expertise and results demonstrated by Caprion as part of an initial
contract awarded in 2004 and still in progress.
"We are very pleased to be granted the opportunity to expand our
infectious disease research program with NIAID into the area of clinical
biomarker discovery and validation," said Martin LeBlanc, President and CEO at
Caprion. "This second major contract award from the NIAID provides further
evidence of Caprion's solid scientific capabilities and industry leadership
position as a proteomics and biomarker services provider."
Caprion will retain rights to commercialize candidate biomarkers and
diagnostic products discovered in this project.
About Caprion Proteomics, Inc.
Caprion Proteomics is the leading provider of proteomics based services
to the pharmaceutical industry. Caprion's proprietary proteomics discovery
technology, CellCarta(R), is a gel-free, label-free mass spectrometry platform
that enables a comprehensive, quantitative and robust measurement of the
protein expression differences across large sets of biological samples.
Caprion has been providing biomarker and target identification services since
2002, and has served such clients as Pfizer, Johnson & Johnson, Abbott
Laboratories, Biogen Idec, Daiichi-Sankyo, Mitsubishi-Tanabe, Wyeth,
AstraZeneca, Merck, Boehringer Ingelheim, ICOS, Bayer-Schering, EMD-Serono,
Vertex, DebioPharm and Transgene. Caprion also has been awarded two major
5-year Biodefense proteomics research contracts in infectious disease with the
NIH-NIAID. For more information, please visit: http://www.caprion.com.
For further information:
For further information: Didier Jean-Francois of Caprion Proteomics
Inc., +1-514-228-3625, email@example.com